**Core Concept:** ATRIPLA is a combination antiretroviral therapy (ART) drug regimen used for treating HIV infection. This regimen typically consists of three drugs: efavirenz (EFV), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF).

**Why the Correct Answer is Right:** ATRIPLA is a combination of efavirenz, emtricitabine, and tenofovir disoproxil fumarate. These drugs work together to help suppress the replication of the HIV virus and improve the immune system function in patients. Efavirenz (EFV) is an NNRTI (non-nucleoside reverse transcriptase inhibitor), emtricitabine (FTC) is a NRTI (nucleoside reverse transcriptase inhibitor), and tenofovir disoproxil fumarate (TDF) is an NRTI.

**Why Each Wrong Option is Incorrect:**

A. Tenofovir alafenamide (TAF) is another NRTI that could potentially be included in an ART regimen, but it is not part of ATRIPLA.

B. Didanosine (DDC) is another NRTI that could be included in an ART regimen but is not part of ATRIPLA.

C. Lopinavir/ritonavir (LPV/r) is a protease inhibitor, which is not part of ATRIPLA. LPV/r is often used in combination with another NNRTI, NRTI, or integrase inhibitor.

D. Raltegravir (RAL) is an integrase inhibitor, which is not part of ATRIPLA. RAL is typically used in combination with other ART drugs, such as an NNRTI and NRTI.

**Clinical Pearl:** When selecting antiretroviral therapy (ART) regimens, it is essential to consider the specific drug classes and their interactions with other ART drugs. The correct combination of drugs depends on factors like patient's viral load, CD4 count, and potential drug-drug interactions. A well-informed choice of ART regimen ensures optimal treatment outcomes and reduces potential side effects.